Journal article · 2026 · Open access

Evaluating generative models for structure-based drug discovery from de novo design to lead optimization

Duanhua Cao, Zhehuan Fan, Jie Yu, Mingan Chen, Xinyu Jiang, Xia Sheng, Xingyou Wang, Chuanlong Zeng, Xiaomin Luo, Dan Teng, Mingyue Zheng

Nature Communications, 17(1) · Published 1 October 2026 · DOI 10.1038/s41467-026-78105-8

Open PDFView at the publisherCite this paper

In brief

“Evaluating generative models for structure-based drug discovery from de novo design to lead optimization” is a 2026 journal article by Duanhua Cao and 10 co-authors, published in Nature Communications. OpenAlex counts 8 citations as of 18 November 2026, which puts it in the top 2% of works published in 2026 by citations. It is open access under a CC BY-NC-ND licence: the full text is free to read at Nature Communications.

Citations
8
Most cited in
2026 (8)
Field-weighted impact
9.49
References
61
Authors
11

Abstract

Advances in protein structure prediction have created opportunities for structure-based drug design, yet translating structural knowledge into actionable small-molecule ligands remains difficult. Existing benchmarks often use simplified datasets and computational surrogates that poorly capture the heterogeneity and constraints of real-world drug discovery. We introduce MolGenBench, a comprehensive benchmark for de novo molecular generation and hit-to-lead optimization built on a large, structurally diverse dataset. Evaluation of 17 leading methods reveals persistent limitations, including weak virtual-screening performance, limited coverage of target-specific bioactive space, frequent high-risk structural motifs, poor target awareness, and reduced generalization to unseen proteins. Although some models improve three-dimensional conformation generation, they still struggle to produce active molecules reliably. MolGenBench provides standardized data, metrics, and analyses that connect structural prediction with practical molecular design and guide the development of more effective structure-based generative models. Protein structures are increasingly available but turning them into useful drug candidates remains difficult. Here, Cao et al. introduce MolGenBench to assess 17 generative methods and reveal gaps in activity, target awareness and generalization.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Cao, D., Fan, Z., Yu, J., Chen, M., Jiang, X., Sheng, X., Wang, X., Zeng, C., Luo, X., Teng, D., & Zheng, M. (2026). Evaluating generative models for structure-based drug discovery from de novo design to lead optimization. Nature Communications, 17(1). https://doi.org/10.1038/s41467-026-78105-8

MLA 9

Cao, Duanhua, et al. “Evaluating generative models for structure-based drug discovery from de novo design to lead optimization.” Nature Communications, vol. 17, no. 1, 2026. https://doi.org/10.1038/s41467-026-78105-8.

Chicago

Cao, Duanhua, Zhehuan Fan, Jie Yu, Mingan Chen, Xinyu Jiang, Xia Sheng, Xingyou Wang, et al. 2026. “Evaluating generative models for structure-based drug discovery from de novo design to lead optimization.” Nature Communications 17 (1). https://doi.org/10.1038/s41467-026-78105-8.

Harvard

Cao, D. et al. (2026) ‘Evaluating generative models for structure-based drug discovery from de novo design to lead optimization’, Nature Communications, 17(1). doi:10.1038/s41467-026-78105-8.

IEEE

D. Cao et al., “Evaluating generative models for structure-based drug discovery from de novo design to lead optimization,” Nature Communications, vol. 17, no. 1, 2026, doi: 10.1038/s41467-026-78105-8.

BibTeX

@article{cao2026evaluating,
  title     = {{Evaluating generative models for structure-based drug discovery from de novo design to lead optimization}},
  author    = {Cao, Duanhua and Fan, Zhehuan and Yu, Jie and Chen, Mingan and Jiang, Xinyu and Sheng, Xia and Wang, Xingyou and Zeng, Chuanlong and Luo, Xiaomin and Teng, Dan and Zheng, Mingyue},
  journal   = {Nature Communications},
  year      = {2026},
  volume    = {17},
  number    = {1},
  doi       = {10.1038/s41467-026-78105-8},
  url       = {https://doi.org/10.1038/s41467-026-78105-8}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods

  • generative models
  • structure-based drug design
  • de novo molecular design
  • hit-to-lead optimization
  • protein structure prediction
  • benchmarking
  • virtual screening
  • small-molecule ligands

Work with this paper

Most-cited papers in Pharmacology, Toxicology and Pharmaceutics

All highly cited Pharmacology, Toxicology and Pharmaceutics papers

Questions about this paper

How do I cite this paper in APA style?

Cao, D., Fan, Z., Yu, J., Chen, M., Jiang, X., Sheng, X., Wang, X., Zeng, C., Luo, X., Teng, D., & Zheng, M. (2026). Evaluating generative models for structure-based drug discovery from de novo design to lead optimization. Nature Communications, 17(1). https://doi.org/10.1038/s41467-026-78105-8

How many times has this paper been cited?

8 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Communications: sign in and open the PDF from this page.

Who wrote this paper?

Duanhua Cao, Zhehuan Fan, Jie Yu, Mingan Chen, Xinyu Jiang, Xia Sheng, Xingyou Wang, Chuanlong Zeng, Xiaomin Luo, Dan Teng, Mingyue Zheng.

What is the DOI of this paper?

10.1038/s41467-026-78105-8, permanently at https://doi.org/10.1038/s41467-026-78105-8. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.